AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Atlassian Corp's CEO, Co-Founder Cannon-Brookes Sells 2934 Shares at $154.84/Share
ByAinvest
Thursday, Dec 4, 2025 5:34 pm ET1min read
Atlassian Corp[TEAM] has announced that Michael Cannon-Brookes, Director, 10% Owner, CEO, and Co-Founder, has made several sales of company shares on December 3, 2025. Cannon-Brookes sold 2934 shares at $154.84 per share, 150 shares at $152.53 per share, 959 shares at $156.66 per share, 1550 shares at $153.88 per share, and 2072 shares at $155.76 per share. Additionally, Scott Farquhar, Director and 10% Owner, also made several sales of company shares on the same day, including 150 shares at $152.53 per share, 1550 shares at $153.88 per share, 959 shares at $156.66 per share, 2072 shares at $155.76 per share, and 2934 shares at $154.84 per share.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet